Clinical trials located in

Barakaldo

Barakaldo city is located in Spain. Currently, 13 clinical trials are being conducted in this city.

Barakaldo, located in the Basque Country of Spain, is a vibrant industrial city with a rich history. Nestled on the left bank of the Estuary of Bilbao, it is part of the Greater Bilbao region. Established in the 13th century, Barakaldo has evolved from its medieval roots into a modern city with a strong industrial base, particularly in steel production and shipbuilding. The city is also known for its green spaces, including the Botanic Garden, which showcases a diverse range of plant species. Barakaldo’s cultural scene is lively, with the BEC (Bilbao Exhibition Centre) hosting numerous events and exhibitions.

  • CT-EU-00023235

    Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Understanding the effects of tominersen on early-stage Huntington’s Disease

    This clinical trial focuses on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease-a genetic disorder characterised by the progressive breakdown of nerve cells in the brain. This study aims to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses or placebo directly into the spinal cord to target the areas of the brain most affected by the disease. Participants’ health status will be rigorously monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional wellbeing. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study represents an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    AustriaDenmarkFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Testing new medication for safety and effect on Huntington’s disease

    This clinical trial evaluates the safety and efficacy of PTC518, a medication for Huntington’s Disease. The study involves adults with genetically confirmed Huntington’s Disease, receiving either PTC518 or a placebo. Over 12 months, the trial will monitor changes in symptoms and any adverse effects. The goal is to understand if PTC518 can safely and effectively manage Huntington’s Disease symptoms, potentially offering a new treatment option for those affected by this neurodegenerative disorder.

    AustriaFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Testing tovorafenib in treating low-grade glioma

    This study is a comparative test between tovorafenib (DAY101) and the standard chemotherapy typically administered to children with low-grade glioma, a specific type of brain tumor. The experiment involves approximately 400 children who have not yet received treatment for their glioma. The participants will be divided into two groups. In the first group, children will be administered DAY101, taking it every 28 days until one of the following events occurs: they no longer benefit from the treatment, it becomes unsafe, they choose to leave the experiment, or the experiment concludes. In the second group, children will receive one of three common chemotherapy drugs selected by their doctor, and they will continue with the treatment until similar circumstances prompt a change, as outlined for the first group. If the tumor continues to grow while on DAY101 but the treatment remains beneficial, participants can continue taking it. Likewise, if the tumor continues to grow while on chemotherapy, participants can stop and transition to DAY101.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwaySloveniaSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • New treatment study for multiple system atrophy patients

    This study investigates TAK-341’s effectiveness in treating multiple system atrophy (MSA), a progressive neurological disorder. Around 138 participants will receive either TAK-341 or a placebo through regular intravenous infusions over 52 weeks. The trial primarily measures changes in the Unified Multiple System Atrophy Rating Scale Part I (UMSARS) to assess improvement in symptoms. This research is significant for understanding TAK-341’s potential in managing MSA, providing new insights into treatment options for this challenging condition.

    AustriaDenmarkFranceGermanyItalyPortugalSpainUnited Kingdom
  • Study of new combined therapy for untreatable lung membrane cancer

    This study is testing a new treatment for pleural mesothelioma, a type of lung cancer. It compares a new drug, Volrustomig combined with carboplatin and pemetrexed, against drugs chosen by the researcher, which could include platinum, pemetrexed, nivolumab, or ipilimumab. The goal is to see which treatment works better and is safer. About 600 adults with advanced mesothelioma that can’t be removed by surgery will participate. The study will look at how long patients live with each treatment and other health factors.

    BelgiumDenmarkFranceGermanyItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Investigating the potential treatment of a rare blood disorder—Thrombotic thrombocytopenic purpura

    This study analyzes the effects of TAK-755 on patients with congenital thrombotic thrombocytopenic purpura, a rare blood disorder. Thrombotic thrombocytopenic purpura (TTP) leads to blood clotting in small blood vessels, which can cause serious health problems. The disease is caused by a lack of activity of the enzyme ADAMTS13, which is involved in controlling blood clotting. The study’s leading goal is to evaluate the side effects of TAK-755 and understand how it can help patients who currently have limited treatment options. Treatment proceeds in two ways, the new drug will be administered weekly or every other week to prevent acute TTP events—the “prophylactic” cohort. The second option is to use TAK-755 to control an acute TTP event when it happens.

    AustriaFranceGermanyItalyPolandSpain

See more clinical trials in other cities in Spain:

.